SEC Form 4Coverage since Jun 16, 2026
$BLTE insider trading
Over the last 12 months, Belite Bio insiders reported no purchases and 2 sales totaling $2.9M across SEC Form 4 filings.
- Bought · 12m
- — 0 events
- Sold · 12m
- $2.9M 2 events
- Events · 12m
- 2 Form 4 filings, grouped
- Insiders · 12m
- 1 distinct reporters
- 10b5-1 share
- 0% pre-arranged plans
Side
Price · $BLTE · 12Mvia TradingView
Top insiders · 12m
Scholl Hendrik PeterChief Medical Officer2× · $2.9M
All insider trades
2 events
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jun 18, 2026 | Scholl Hendrik PeterChief Medical Officer · O | ▼ Sale | 10,000 | $145.24 | $1.5M | -40% | 5 tranches · indirect |
| Jun 16, 2026 | Scholl Hendrik PeterChief Medical Officer · O | ▼ Sale | 10,000 | $140.57 | $1.4M | -28.6% | 8 tranches · indirect |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $BLTE feed.